December 23rd local time, the government of São Paulo, Brazil, and the Butantan Research Institute, an authoritative medical research institute, held a press conference and announced that the completion of the third phase of the human trial of the Kelifo coronavirus vaccine developed by Beijing Kexing Zhongwei Biotechnology Co., Ltd. The test results show that China’s coronavirus vaccine is effective and safe.
Dimas Kovas, director of the Butantan Institute, said that volunteers were injected with more than 20,000 doses of vaccine during the trial. Judging from the available test data, the Kelif vaccine is the safest coronavirus vaccine on the market.
The effectiveness of the Kelifou coronavirus vaccine exceeds the minimum validity standard required by the World Health Organization, and the Butantan Institute will formally apply to the Brazilian National Health Surveillance Agency for registration of the vaccine.
Brazil is the first country in the world to complete the phase III trial of the Kelif vaccine, and the third phase of the vaccine is also under way in Indonesia, Turkey and Chile.
Kovas, director of the Butantan Institute, said that Kochen will further analyze the results of the third phase of the test in Brazil and may publish the results within 15 days.
In the early morning of the 24th local time, a batch of 5.5 million doses of Kelrafo coronavirus vaccine shipped by China arrived at Villacopos International Airport in Campinas, São Paulo.
The state of São Paulo will receive another batch of 2 million doses of COVID-19 next week. Jean Gollinghitene, director of the state of São Paulo, Brazil, said that vaccination against the people of the state will start vaccinated against the coronavirus on January 25, 2021 as planned.